Gufic BioSciences Quarterly Results for Trading Insights
In Mar 2026, Gufic BioSciences (GUFICBIO) reported revenue ₹251 Cr and net profit ₹22 Cr — revenue +22.4% YoY. Browse GUFICBIO cash flow statement for revenue, profit, balance sheet and cash flow data.
GUFICBIO Quarterly Results — Revenue, Profit & EPS Highlights
Gufic BioSciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore GUFICBIO price trends to track price trends across different timeframes.
- Revenue of ₹251 Cr in Mar 2026 (-3.8% vs Jun 2026, +22.4% vs Mar 2025)
- Net Profit of ₹22 Cr in Mar 2026 (+0.0% vs Jun 2026, +175.0% vs Mar 2025)
- EBITDA of ₹46 Cr in Mar 2026 (-2.1% vs Jun 2026)
- Operating Margin of 19.0% in Mar 2026 (+1.0pp vs Jun 2026)
- Earnings Per Share of ₹2.18 in Mar 2026 (-1.8% vs Jun 2026)
Gufic BioSciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GUFICBIO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 251 | 261 | 239 | 205 | 225 | -3.8% | 22.4% |
| Net Profit (₹ Cr) | 22 | 22 | 17 | 8 | 13 | - | - |
| EBITDA (₹ Cr) | 46 | 47 | 40 | 27 | 34 | - | - |
| EPS (₹) | 2.18 | 2.22 | 1.68 | 0.77 | 1.30 | - | - |
| Operating Margin (%) | 19.0% | 18.0% | 16.0% | 13.0% | 15.0% | - | - |
GUFICBIO Share Price Trend — 1-Year Movement Across Quarterly Results
Gufic BioSciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Gufic BioSciences screener.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GUFICBIO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Gufic BioSciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1875.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 165.9 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8588.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4971.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.9 |
|
Cipla
Mar 2026 |
₹117,137.57 Cr | 1431.1 | 6,612 | 543 | -9.3% | - | 8.2% | 208.3 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1115.6 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.2 |
All amounts in ₹ Crores